EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics

Hyo-Jin Kim iD, Jeong-Hyung Lee iD, Cheol Hwangbo iD

Aging Cell · 2026

DOI: 10.1111/acel.70757 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Aging Cell, 2026. Verfasst von Hyo-Jin Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Science, College of Natural Sciences, Gyeongsang National University, Jinju, Republic of Korea. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Senotherapeutics, Endothelium, Vascular, Aging. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Glocal University 30 at Gyeongsang National University in 2025.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditionally viewed as a classic sentinel of innate immunity, Toll‐like receptor 4 (TLR4) has emerged as a crucial pathological driver within the vascular endothelium, with its identity dictated by cell‐type specificity, microenvironmental context, and fluctuating expression levels. This review critically examines the dual functional nature of endothelial TLR4, delineating how it transitions into a primary driver of vascular aging and organ‐specific vascular pathologies. The profound spatial, temporal, and cellular heterogeneities of TLR4 signaling expose the fundamental inadequacies of conventional systemic pan‐TLR4 blockade, which has repeatedly failed in clinical trials due to severe immunosuppression and metabolic disruptions. To bypass these limitations, we propose a precision senotherapeutic framework utilizing advanced drug delivery systems—such as Vascular cell adhesion molecule‐1 (VCAM‐1) or E‐selectin‐targeted nanoparticles and genetically engineered plant‐derived exosomes—to compartmentalize TLR4 inhibition within pathologically altered endothelial sub‐populations. By shifting the clinical paradigm from indiscriminate receptor suppression to spatiotemporal fine‐tuning, this conceptual framework provides a rational blueprint for next‐generation anti‐aging therapies aimed at restoring vascular homeostasis throughout the aging process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4SenotherapeuticsEndothelium, VascularAgingCellular SenescenceEndothelial CellsHumansAnimals

Stichwörter der Autor:innen

TLR4endothelial cellssenomorphic therapytargeted drug deliveryvascular aging

Substanzen

Toll-Like Receptor 4Senotherapeutics

Autor:innen und Institutionen

  • Division of Life Science, College of Natural Sciences, Gyeongsang National University, Jinju, Republic of Korea.
  • Plant Molecular Biology and Biotechnology Research Center (PMBBRC) and Research Institute of Life Sciences, Gyeongsang National University, Jinju, Republic of Korea.
  • Department of Biochemistry (BK21 Four), College of Natural Sciences, Kangwon National University, Chuncheon, Republic of Korea.
  • Division of Applied Life Science (BK21 Four), Research Institute of Life Sciences, Gyeongsang National University, Jinju, Republic of Korea.

ORCID-Profile: Hyo-Jin Kim, Jeong-Hyung Lee, Cheol Hwangbo

Förderung

  • National Research Foundation of Korea
  • Glocal University 30 at Gyeongsang National University in 2025

Zitieren

APA

Kim, H. J., Lee, J. H., & Hwangbo, C. (2026). Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics. Aging Cell. https://doi.org/10.1111/acel.70757

Vancouver

Kim HJ, Lee JH, Hwangbo C. Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics. Aging Cell. 2026. doi:10.1111/acel.70757

BibTeX
@article{Kim2026,
  author = {Kim, Hyo-Jin and Lee, Jeong-Hyung and Hwangbo, Cheol},
  title = {Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics},
  journal = {Aging Cell},
  year = {2026},
  doi = {10.1111/acel.70757}
}
Kostenlos starten →